Sizofiran

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Sizofiran
Accession Number
DB13128
Type
Small Molecule
Groups
Investigational
Description

A beta-D-glucan obtained from the Aphyllophoral fungus Schizophyllum commune. It is used as an immunoadjuvant in the treatment of neoplasms, especially tumors found in the stomach. Sizofiran has been used in trials studying the treatment of Cervical Cancer.

Structure
Thumb
Synonyms
  • Sizofiranum
  • Sonifilan
External IDs
Not Available
Product Ingredients
Not Available
Approved Prescription Products
Not Available
Approved Generic Prescription Products
Not Available
Approved Over the Counter Products
Not Available
Unapproved/Other Products
Not Available
International/Other Brands
Not Available
Brand mixtures
Not Available
Categories
UNII
7F763NNC9X
CAS number
9050-67-3
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Sonifilan.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Sonifilan.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sonifilan.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Sonifilan.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Sonifilan.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Sonifilan.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Sonifilan.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sonifilan.Approved, Investigational
OleandrinAnvirzel may decrease the cardiotoxic activities of Sonifilan.Experimental
OuabainOuabain may decrease the cardiotoxic activities of Sonifilan.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sonifilan.Approved, Vet Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Sonifilan.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference
Not Available
General References
Not Available
External Links
Not Available
ATC Codes
Not Available
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1RecruitingTreatmentCervical Cancers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key

Taxonomy

Classification
Not classified
Drug created on October 20, 2016 21:31 / Updated on June 28, 2017 10:04